Drug Profile
ImmuRAIT-Re-188
Alternative Names: ImmuRAIT-rhenium-188Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antibodies; Radioisotopes
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 29 Nov 2000 Discontinued-II for Colorectal cancer in USA (Unknown route)
- 16 Aug 1996 Suspended-II for Colorectal cancer in USA (Unknown route)